You are here

Bluebird Bio

Bluebird won't play off Vertex in deciding price for its lovo-cel gene therapy, exec says

Bluebird won't play off Vertex in deciding price for its lovo-cel gene therapy, exec says

Fierce Pharma

Vertex Pharmaceuticals

sickle cell disease

Flag link:

Two Sickle Cell Disease Gene Therapies May Soon Be Approved By FDA

Two Sickle Cell Disease Gene Therapies May Soon Be Approved By FDA

Forbes

sickle cell disease

Vertex Pharmaceutical

CRISPR Therapeutics

Flag link:

Bluebird bio to sell sickle cell FDA voucher for $103 mln if therapy approved

Bluebird bio to sell sickle cell FDA voucher for $103 mln if therapy approved

Reuters

priority review vouchers

sickle cell disease

Flag link:

Bluebird taps Lonza to boost manufacturing capacity for its gene therapies Zynteglo, Skysona

Bluebird taps Lonza to boost manufacturing capacity for its gene therapies Zynteglo, Skysona

Fierce Pharma

drug manufacturing

Flag link:

Bluebird’s Lovo-Cel Gene Therapy for SCD Will Not Face FDA Adcomm

Bluebird’s Lovo-Cel Gene Therapy for SCD Will Not Face FDA Adcomm

BioSpace

sickle cell disease

Flag link:

Bluebird touts Zynteglo, Skysona launch progress as FDA decision on sickle cell therapy nears

Bluebird touts Zynteglo, Skysona launch progress as FDA decision on sickle cell therapy nears

Fierce Pharma

sickle cell disease

Flag link:

U.S. watchdog lifts price estimate for Bluebird, Vertex/CRISPR gene therapies to $2.1 million

U.S. watchdog lifts price estimate for Bluebird, Vertex/CRISPR gene therapies to $2.1 million

Reuters

Vertex Pharmaceuticals

CRISPR Therapeutics

sickle cell disease

Flag link:

Bluebird, playing catch-up, gets decision date for sickle cell gene therapy

Bluebird, playing catch-up, gets decision date for sickle cell gene therapy

BioPharma Dive

sickle cell disease

Flag link:

Death triggers pause of 2seventy CAR-T cell therapy leukemia trial

Death triggers pause of 2seventy CAR-T cell therapy leukemia trial

Fierce Biotech

clinical trials

Flag link:

Gene Therapies Are Still Hampered By Substantial Delays Between Approval And Launch

Gene Therapies Are Still Hampered By Substantial Delays Between Approval And Launch

Forbes

Flag link:

Bluebird Bio submits BLA for sickle cell disease gene therapy

Bluebird Bio submits BLA for sickle cell disease gene therapy

Biopharma Reporter

sickle cell disease

Flag link:

Bluebird to miss Q1 deadline for lovo-cel filing, shares sliced

Bluebird to miss Q1 deadline for lovo-cel filing, shares sliced

Endpoints

sickle cell disease

Flag link:

Medicaid, with planned payment pilot, girds for influx of pricey gene therapies

Medicaid, with planned payment pilot, girds for influx of pricey gene therapies

BioPharma Dive

sickle cell disease

Vertex Pharmaceuticals

CRISPR Therapeutics

Flag link:

Bluebird hopes to raise upwards of $100M by selling shares

Bluebird hopes to raise upwards of $100M by selling shares

Endpoints

Flag link:

Moderna Gets Good News, but Another Biotech Stock Is Falling Again

Moderna Gets Good News, but Another Biotech Stock Is Falling Again

Motley Fool

Moderna Therapeutics

Flag link:

FDA Lifts Partial Clinical Hold On Bluebird Bio's Sickle Cell Disease Studies

FDA Lifts Partial Clinical Hold On Bluebird Bio's Sickle Cell Disease Studies

NASDAQ

clinical trials

sickle cell disease

Flag link:

J&J’s next myeloma drug, Argenx’s second act and a new question for Bluebird: 3 ASH takeaways

J&J’s next myeloma drug, Argenx’s second act and a new question for Bluebird: 3 ASH takeaways

BioPharma Dive

Multiple Myeloma

Flag link:

ASH: Despite partial clinical hold, bluebird's sickle cell gene therapy remains on track

ASH: Despite partial clinical hold, bluebird's sickle cell gene therapy remains on track

Fierce Pharma

sickle cell disease

Flag link:

Pages